MiRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling

Molecular Medicine Reports

Volumn 7, Issue 5, 2013, Pages 1579-1584

  Chen, Yong ^a   Sun, Ying ^b   Chen, Longbang ^c   Xu, Xingxiang ^a   Zhang, Xizhi ^a   Wang, Buhai ^a   Min, Lingfeng ^a   Liu, Wei ^d  

^a NORTHERN JIANGSU PEOPLE S HOSPITAL   (China)

^b HEBEI UNITED UNIVERSITY   (China)

^c NANJING UNIVERSITY   (China)

^d Hebei Provincial Tumor Hospital   (China)

Author keywords

Akt; Breast cancer; Doxorubicin resistance; E cadherin; MiRNA 200c; PTEN

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DOXORUBICIN; MICRORNA 200C; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

BREAST NEOPLASMS; CADHERINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MCF-7 CELLS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84876004859     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1403     Document Type: Article

References (29)

1. Roberti A, La Sala D and Cinti C: Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol 207: 571-581, 2006.
2. Glasspool RM, Teodoridis JM and Brown R: Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 94: 1087-1092, 2006.
3. Iwasa Y, Nowak MA and Michor F: Evolution of resistance during clonal expansion. Genetics 172: 2557-2566, 2006.
4. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
5. Slaby O, Jancovicova J, Lakomy R, et al: Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res 29: 90, 2010.
6. Philippidou D, Schmitt M, Moser D, et al: Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res 70: 4163-4173, 2010.
7. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G and Voros D: Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog Dec 27, 2011 (Epub ahead of print). doi: 10.1002/mc.21864.
8. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK and Richer JK: MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8: 1055-1066, 2009.
9. Ceppi P, Mudduluru G, Kumarswamy R, et al: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8: 1207-1216, 2010.
10. Kovalchuk O, Filkowski J, Meservy J, et al: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7: 2152-2159, 2008.
11. Li Z, Wang L, Zhang W, et al: Restoring E-cadherin-mediated cell-cell adhesion increases PTEN protein level and stability in human breast carcinoma cells. Biochem Biophys Res Commun 363: 165-170, 2007.
12. Kim SM, Kim JS, Kim JH, et al: Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. Cancer Lett 296: 150-159, 2010.
13. Park SM, Gaur AB, Lengyel E and Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22: 894-907, 2008.
14. Lau MT, Klausen C and Leung PC: E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression. Oncogene 30: 2753-2766, 2011.
15. Selga E, Morales C, Noé V, Peinado MA and Ciudad CJ: Role of caveolin 1, E-cadherin, Enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells. BMC Med Genomics 1: 35, 2008.
16. Hurteau GJ, Carlson JA, Spivack SD and Brock GJ: Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 67: 7972-7976, 2007.
17. Eger A, Aigner K, Sonderegger S, et al: DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24: 2375-2385, 2005.
18. Tryndyak VP, Beland FA and Pogribny IP: E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 126: 2575-2583, 2010.
19. Hurteau GJ, Spivack SD and Brock GJ: Potential mRNA degradation targets of hsa-miR-200c, identified using informatics and qRT-PCR. Cell Cycle 5: 1951-1956, 2006.
20. Junxia W, Ping G, Yuan H, et al: Double strand RNA-guided endogeneous E-cadherin up-regulation induces the apoptosis and inhibits proliferation of breast carcinoma cells in vitro and in vivo. Cancer Sci 101: 1790-1796, 2010.
21. Sasaki CY, Lin HC and Passaniti A: Expression of E-cadherin reduces bcl-2 expression and increases sensitivity to etoposide-induced apoptosis. Int J Cancer 86: 660-666, 2000.
22. Ferreira P, Oliveira MJ, Beraldi E, et al: Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro. Exp Cell Res 310: 99-104, 2005.
23. Black PC, Brown GA, Inamoto T, et al: Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 14: 1478-1486, 2008.
24. Witta SE, Gemmill RM, Hirsch FR, et al: Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66: 944-950, 2006.
25. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
26. Oki E, Baba H, Tokunaga E, et al: Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 117: 376-380, 2005.
27. Stassi G, Garofalo M, Zerilli M, et al: PED mediates AKT-dependent chemoresistance in human breast cancer cells. Cancer Res 65: 6668-6675, 2005.
28. Myers MP, Pass I, Batty IH, et al: The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 95: 13513-13518, 1998.
29. Lee S, Choi EJ, Jin C and Kim DH: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97: 26-34, 2005.